Compare · EPRX vs IMV
EPRX vs IMV
Side-by-side comparison of Eupraxia Pharmaceuticals Inc. (EPRX) and IMV Inc. (IMV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EPRX and IMV operate in Pharmaceuticals and Biotechnology (Health Care), so they compete in similar markets.
- EPRX is the larger of the two at $446.2M, about 5.0x IMV ($89.5M).
- EPRX has hit the wire 6 times in the past 4 weeks while IMV has been quiet.
- EPRX has more recent analyst coverage (9 ratings vs 2 for IMV).
- Company
- Eupraxia Pharmaceuticals Inc.
- IMV Inc.
- Price
- $6.61-2.51%
- $0.80+2.92%
- Market cap
- $446.2M
- $89.5M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Pharmaceuticals and Biotechnology
- Pharmaceuticals and Biotechnology
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 6
- 0
- Recent ratings
- 9
- 2
IMV Inc.
IMV Inc., a biopharmaceutical company, focuses on the development of cancer immunotherapies and vaccines against infectious diseases using its DPX delivery technology platform. The company's lead drug candidate includes maveropepimut-S (DPX-Survivac), a T cell therapy, which is in three Phase II clinical trials across 6 different cancer indications with and without Merck's Keytruda; and Phase II clinical trials for the treatment of ovarian cancer, and recurrent and refractory diffuse large B cell lymphoma. It is also developing DPX-COVID-19, a second-generation vaccine against severe acute respiratory syndrome coronavirus 2; and DPX-RSV, a vaccine candidate, which has completed Phase I clinical trials for the treatment of respiratory syncytial virus strain A, as well as DPX-SurMAGE for the treatment of bladder cancer and DPX-BRAF to treat melanoma patients. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Latest EPRX
- SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.
- Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis
- SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.
- Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences
- SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.
- Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis
- Wedbush initiated coverage on Eupraxia Pharmaceuticals with a new price target
- SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.
- Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences
- SEC Form SUPPL filed by Eupraxia Pharmaceuticals Inc.
Latest IMV
- SEC Form 15-12G filed by IMV Inc.
- SEC Form F-10POS filed by IMV Inc.
- SEC Form F-10POS filed by IMV Inc.
- SEC Form F-10POS filed by IMV Inc.
- SEC Form S-8 POS filed by IMV Inc.
- SEC Form S-8 POS filed by IMV Inc.
- SEC Form S-8 POS filed by IMV Inc.
- SEC Form S-8 POS filed by IMV Inc.
- SEC Form S-8 POS filed by IMV Inc.
- SEC Form 6-K filed by IMV Inc.